You are here
TRU NIAGEN® PRO to be Featured at the North American Menopause Society (NAMS) Annual Meeting
Women’s health practitioners now have access to TRU NIAGEN® PRO for aging patients
LOS ANGELES, Oct. 03, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that it will highlight its new TRU NIAGEN® PRO product at the NAMS Annual Meeting 2018 in San Diego, CA, beginning today through Oct. 6.
“Aging is so much more than skin deep—down to the cellular level. NAD (nicotinamide adenine dinucleotide) is critical for mitochondria function, and healthy mitochondria are a vital part of healthy living as we age,” says gynecologist and NAMS member Alyssa Dweck, MS, MD, FACOG, Assistant Clinical Professor in the Department of Obstetrics, Gynecology and Reproductive Science at the Mount Sinai School of Medicine and a consultant at the Vincent Obstetrics and Gynecology Service at Massachusetts General Hospital. “Increasing NAD may further boost energy levels before, during, and after the menopausal transition.”
The sole active ingredient in Tru Niagen Pro is NIAGEN® nicotinamide riboside, a unique form of vitamin B3 clinically proven to safely increase one’s levels of NAD (nicotinamide adenine dinucleotide). Decreased NAD levels have been associated with many age-related changes in overall health.
Tru Niagen team members will be at the event, available to discuss the latest published human evidence, to register practitioners on the new NAD education hub and discuss how they can bring Tru Niagen Pro directly to their patients. Practitioners should visit booth #116 early to get a complimentary bottle of Tru Niagen Pro, as supplies are limited.
For additional information on Tru Niagen Pro, visit practitioner.truniagen.com.
ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.
About TRU NIAGEN®:
TRU NIAGEN® is a branded dietary supplement brought to market by key nicotinamide riboside innovator and patent holder, ChromaDex. NIAGEN® nicotinamide riboside (NR), also supplied by ChromaDex, is the sole active ingredient in TRU NIAGEN®. Multiple clinical trials demonstrate NIAGEN® is proven to boost NAD (nicotinamide adenine dinucleotide) levels, which decline with age. Only NIAGEN® has twice been successfully reviewed under FDA's new dietary ingredient (“NDI”) notification program, and has also been successfully notified to the FDA as generally recognized as safe (“GRAS”).
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 30, 2017, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof. ChromaDex provided research materials and a portion of the grant funding as a collaborator for the study.
ChromaDex Media Contact:
Alex Worsham, Director of Strategic Partnerships
ChromaDex Investor Relations Contact:
Brianna Gerber, Sr. Director of FP&A and Investor Relations